Aytu BioPharma Past Earnings Performance
Past criteria checks 0/6
Aytu BioPharma's earnings have been declining at an average annual rate of -44.8%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 58% per year.
Key information
-44.8%
Earnings growth rate
73.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 58.0% |
| Return on equity | -170.6% |
| Net Margin | -74.0% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Aytu BioPharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 106 | -78 | 71 | 11 |
| 30 Sep 22 | 102 | -83 | 70 | 14 |
| 30 Jun 22 | 97 | -110 | 70 | 14 |
| 31 Mar 22 | 93 | -111 | 73 | 16 |
| 31 Dec 21 | 82 | -84 | 68 | 11 |
| 30 Sep 21 | 74 | -82 | 62 | 7 |
| 30 Jun 21 | 66 | -58 | 56 | 6 |
| 31 Mar 21 | 57 | -42 | 47 | 2 |
| 31 Dec 20 | 52 | -22 | 42 | 2 |
| 30 Sep 20 | 40 | -13 | 37 | 2 |
| 30 Jun 20 | 28 | -14 | 31 | 2 |
| 31 Mar 20 | 14 | -25 | 24 | 0 |
| 31 Dec 19 | 9 | -24 | 22 | 0 |
| 30 Sep 19 | 7 | -29 | 21 | 1 |
| 30 Jun 19 | 7 | -27 | 19 | 1 |
| 31 Mar 19 | 7 | -12 | 18 | 1 |
| 31 Dec 18 | 5 | -10 | 18 | 1 |
| 30 Sep 18 | 4 | -9 | 17 | 0 |
| 30 Jun 18 | 4 | -10 | 18 | 0 |
| 31 Mar 18 | 4 | -17 | 17 | 0 |
| 31 Dec 17 | 4 | -20 | 17 | 1 |
| 30 Sep 17 | 4 | -21 | 16 | 1 |
| 30 Jun 17 | 3 | -23 | 17 | 1 |
| 31 Mar 17 | 3 | -31 | 17 | 4 |
| 31 Dec 16 | 3 | -33 | 15 | 5 |
| 30 Sep 16 | 3 | -32 | 13 | 6 |
| 30 Jun 16 | 3 | -28 | 9 | 6 |
Quality Earnings: AY20 is currently unprofitable.
Growing Profit Margin: AY20 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AY20 is unprofitable, and losses have increased over the past 5 years at a rate of 44.8% per year.
Accelerating Growth: Unable to compare AY20's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AY20 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: AY20 has a negative Return on Equity (-170.61%), as it is currently unprofitable.